The Indian Pharmaceutical industry has experienced significant growth and a positive outlook in 2023. The sector has expanded its global footprint, with India being the largest provider of generic medications worldwide, occupying a 20 percent share of the global supply by volume.
The pharmaceutical industry has been growing rapidly in recent years due to several factors such as increasing demand for generic drugs, growing healthcare infrastructure, and favourable government policies. The Indian pharmaceutical market continues to clock a growth of 9 to 10 percent.
Furthermore, the Government has also implemented various initiatives to boost the industry, such as the Production Linked Incentive (PLI) Scheme, which aims to promote local manufacturing, and the Scheme for Strengthening the Pharmaceuticals Industry (SPI), which focuses on MSMEs and pharma clusters in the country.
Listed below are the such Pharma stocks that have delivered a multibagger return and also have a high Piotroski score:
Venus Remedies Ltd:
With a market capitalization of Rs. 481 crores, the shares of Venus Remedies Ltd started Tuesday’s trading session on a higher note at Rs. 352 compared to its previous close of Rs.350.25. During the trading session, the shares hit a high of Rs. 362, gaining around 3 percent and are currently trading at Rs. 358 apiece. The company has a Piotroski score of ‘8’.
Coming onto the company’s financial statements, the revenue decreased by 15 percent from Rs. 167.72 crores during the September quarter to Rs. 143.42 crores in the December quarter. In addition, the net profits declined by 31 percent from Rs. 9.94 crores to Rs. 6.85 crores during the same period.
The shares have delivered a multibagger of 142 percent to its investors in one year. For example, if someone had invested Rs. 1 lakh in these shares a year ago, then the worth of those shares would be Rs. 2.42 lakhs now.
Beryl Drugs Ltd
With a market capitalization of Rs. 20.5 crores, the shares of Beryl Drugs Ltd started Tuesday’s trading session on a flatter note at Rs. 39.99. During the trading session, the shares hit a high of Rs. 40.99, gaining around 1 percent and are currently trading at Rs. 39 apiece. The company has a Piotroski score of ‘9’.
Coming onto the company’s financial statements, the revenue decreased by 5 percent from Rs. 8.09 crores during the September quarter to Rs. 7.66 crores in the December quarter. On a contrasting note, the net profits increased by 15 percent from Rs. 27 lakhs to Rs. 31 lakhs during the same period.
The shares have delivered a multibagger of 212 percent to its investors in one year. For example, if someone had invested Rs. 1 lakh in these shares a year ago, then the worth of those shares would be Rs. 3.12 lakhs now.
Anuh Pharma Ltd
With a market capitalization of Rs. 1,148 crores, the shares of Anuh Pharma Ltd started Tuesday’s trading session on a higher note at Rs. 234 compared to its previous close of Rs. 230. During the trading session, the shares hit a high of Rs. 235, gaining around 2 percent, and are currently trading at Rs. 229 apiece. The company has a Piotroski score of ‘8’.
Coming onto the company’s financial statements, the revenue zoomed by 15 percent from Rs. 150 crores during the September quarter to Rs. 172 crores in the December quarter. In addition, the net profits magnified by 36 percent from Rs. 14 crores to Rs. 19 crores during the same period.
The shares have delivered a multibagger of 165 percent to its investors in one year. For example, if someone had invested Rs. 1 lakh in these shares a year ago, then the worth of those shares would be Rs. 2.65 lakhs now.
Neuland Laboratories Ltd
With a market capitalization of Rs. 9,016 crores, the shares of Neuland Laboratories Ltd started Tuesday’s trading session on a higher note at Rs. 7,100. During the trading session, the shares hit a low of Rs. 6,990, making a loss of around 2 percent and are currently trading at Rs. 7,026 apiece. The company has a Piotroski score of ‘9’.
Coming onto the company’s financial statements, the revenue decreased by 6 percent from Rs. 418 crores during the September quarter to Rs. 393 crores in the December quarter. In addition, the net profits declined by 9 percent from Rs. 89 crores to Rs. 81 crores during the same period.
The shares have delivered a multibagger of 326 percent to its investors in one year. For example, if someone had invested Rs. 1 lakh in these shares a year ago, then the worth of those shares would be Rs. 4.26 lakhs now.
According to the BSE data, Ace Investor Mr Mukul Agrwal, entering the stock in September 2017, currently holds 4 lakh equity shares equivalent to a 3.12 percent stake in this company. The current holding value of his investment amounts to Rs. 283.1 crores.
Written By Vaibhav Patil
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
